Product
Supplier
Encyclopedia
Inquiry
Jinlan 98+ EP/BP/USP Grapiprant buy - large image1
Jinlan 98+ EP/BP/USP Grapiprant buy - image1

Jinlan 98+ EP/BP/USP Grapiprant

Unit Price: Get Latest Price
CAS No.:

415903-37-6

Grade:

medical grade

Content:

98%

Port:

Shanghai/Ningbo/Qingdao

Brand:

Jinlan

Packaging:

25kg/Cardboard Drum

Sample Available:

Yes

Price valid (until):

2026-04-01

Company Type:
Trader
Location:
China
Payment Terms:
100% TT in advance
Average Lead Time:
275 days
Qualification:
Main Products:

Peptides,API,Intermediate

  • Product Details

  • Seller Information

  • Description


      Product Detail  


    Basic Product Description


    CAS Number: 415903-37-6

    Chemical Name: N-(2-Ethylphenyl)-5-methyl-2-(phenylamino)-4-pyrimidinecarboxamide

    Molecular Formula: C₂₀H₂₀N₄O

    Molecular Weight: 332.40 g/mol

    Synonyms: Galliprant®, LY-2493116, Grapiprant free base

    Related Categories: Prostaglandin E2 Receptor 4 (EP4) Antagonist, Veterinary Anti-inflammatory Analgesic, Small Molecule Veterinary API

    Key Highlight: A selective, oral EP4 receptor antagonist developed for veterinary use; indicated for the control of pain and inflammation associated with osteoarthritis in dogs, exerting anti-inflammatory and analgesic effects by blocking PGE2-mediated EP4 signaling without inhibiting cyclooxygenase (COX) enzymes.
    ECHEMI Editorial Reference
    Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin receptor antagonists. This type of molecules is currently in development for veterinary patients. This class of drugs was defined in 2013 by the World Health Organization. Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.|Grapiprant is an orally bioavailable antagonist of the prostaglandin E receptor subtype 4 (EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration of grapiprant, this agent selectively binds to and inhibits the binding of prostaglandin E2 (PGE2) and prevents the activation of the EP4 receptor. This inhibits PGE2-EP4 receptor-mediated signaling and prevents proliferation in tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 receptor inhibition modulates the immune system by preventing both interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. As EP4 is expressed by peripheral sensory neurons, blockade of EP4-mediated signaling may induce an analgesic effect. EP4, a prostanoid receptor subtype, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.

    Basic Info
    Product Name:

    Grapiprant

    Other Name:

    Benzenesulfonamide,N-[[[2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methyl-;N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide;2-Ethyl-4,6-dimethyl-1-[4-[2-[[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]ethyl]phenyl]-1H-imidazo[4,5-c]pyridine;CJ 023423;AAT 007;RQ 00000007;Grapiprant;RQ 7;MR 10A7;1-[2-[4-(2-Ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea;Galliprant

    CAS No.:

    415903-37-6

    Molecular Formula:

    C26H29N5O3S

    InChIKeys:

    InChIKey=HZVLFTCYCLXTGV-UHFFFAOYSA-N

    Molecular Weight:

    491.6

    Exact Mass:

    491.61

    UNII:

    J9F5ZPH7NB

    DSSTox ID:

    DTXSID60194419

    NCI Thesaurus Code:

    C124131

    ATC Code:

    QM01AX92

    Categories:

    Other Chemical Drugs

    Characteristics
    XLogP3:

    4.56

    Melting Point:

    >136 ºC (Grapiprant hydrochloride)

    Water Solubility:

    Insoluble

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides,API,Intermediate

    Location:

    Room 606, Building 1, Fu Yi Commercial Center, Shangcheng District, Hangzhou City, Zhejiang Province - 1

    Payment Terms:

    100% TT in advance

    Average lead Time:

    275 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    51-100

    Year of Establishment:

    2020

    Hangzhou Jinlan Pharm-Drugs Technology Co., Ltd (with its export company Hangzhou Royall Import & Export Co.,Ltd.) is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int' l Airport and Shanghai Pudong Int' l Airport, the transportation and production environment are excellent. JINLAN PHARMA mainly business includes: 1) API, Pharmaceutical Intermediates, CMO, CRO, CDMO and so on. 2) Pharmaceutical Equipment such as: Distilled Water Machinery, Mixer, Sterilizer and so on.

    JINLAN PHARM focus on:

    ■ Contrast Agent

    ■ Anti-COVID APIs

    ■ Respiratory System APIs

    ■ Anti-tumor & Anti-Cancer APIs

    ■ Anti-Diabetes APIs

    ■ Anti-HCV & Anti-HBV APIs

    ■ Anti-HIV APIs

    ■ Peptides

    ■ Pharmaceutical Intermediates

    ■ CMO, CRO, CDMO

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.